Electrocardiographic and echocardiographic abnormalities in urban African people living with HIV in South Africa.
Adult
Anti-Retroviral Agents
/ therapeutic use
CD4 Lymphocyte Count
Cardiovascular Abnormalities
/ diagnostic imaging
Cross-Sectional Studies
Echocardiography
/ methods
Electrocardiography
/ methods
Female
HIV Infections
/ diagnostic imaging
HIV Testing
/ methods
HIV-1
/ pathogenicity
Humans
Male
Middle Aged
Prevalence
Risk Factors
South Africa
/ epidemiology
Urban Population
Viral Load
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
08
2020
accepted:
15
12
2020
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
29
7
2021
Statut:
epublish
Résumé
Studies from high income countries report that HIV-positive people have an impaired systolic and diastolic cardiac function compared to HIV-negative people. It is unclear if results can be translated directly to the Sub-Saharan Africa context. This study assesses electro- and echocardiographic characteristics in an urban African population, comparing HIV-positive people (treated and not yet treated) with HIV-negative controls. We conducted a cross-sectional study in Johannesburg, South Africa. We enrolled HIV-positive participants from three randomized controlled trials that had recruited participants from routine HIV testing programs. HIV-negative controls were recruited from the community. Data were collected on demographics, cardiovascular risk factors, medical history and electrocardiographic and echocardiographic characteristics. In total, 394 HIV-positive participants and 153 controls were enrolled. The mean age of HIV-positive participants was 40±9 years (controls: 35±10 years), and 34% were male (controls: 50%). Of HIV-positive participants 36% were overweight or obese (controls: 44%), 23% had hypertension (controls: 28%) and 12% were current smoker (controls: 37%). Median time since HIV diagnosis was 6.0 years (IQR 2.3-10.0) and median treatment duration was 4.0 years (IQR 0.0-8.0), 50% had undetectable viral load. The frequency of anatomical cardiac abnormalities was low and did not differ between people with and without HIV. We observed no relation between HIV or anti-retroviral therapy (ART) and systolic or diastolic heart function. There was an association between ART use and corrected QT interval: +11.8 ms compared to HIV-negative controls (p<0.01) and +18.9 ms compared to ART-naïve participants (p = 0.01). We also observed a higher left ventricular mass index in participants on ART (+7.8 g/m2, p<0.01), but this association disappeared after adjusting for CD4 cell count, viral load and HIV-duration. The low number of major cardiac abnormalities in this relatively young, well managed urban African HIV-positive population is reassuring. The increase in corrected QT interval and left ventricular mass may contribute to higher cardiac mortality and morbidity in people living with HIV in the long term.
Sections du résumé
BACKGROUND
Studies from high income countries report that HIV-positive people have an impaired systolic and diastolic cardiac function compared to HIV-negative people. It is unclear if results can be translated directly to the Sub-Saharan Africa context. This study assesses electro- and echocardiographic characteristics in an urban African population, comparing HIV-positive people (treated and not yet treated) with HIV-negative controls.
METHODS
We conducted a cross-sectional study in Johannesburg, South Africa. We enrolled HIV-positive participants from three randomized controlled trials that had recruited participants from routine HIV testing programs. HIV-negative controls were recruited from the community. Data were collected on demographics, cardiovascular risk factors, medical history and electrocardiographic and echocardiographic characteristics.
RESULTS
In total, 394 HIV-positive participants and 153 controls were enrolled. The mean age of HIV-positive participants was 40±9 years (controls: 35±10 years), and 34% were male (controls: 50%). Of HIV-positive participants 36% were overweight or obese (controls: 44%), 23% had hypertension (controls: 28%) and 12% were current smoker (controls: 37%). Median time since HIV diagnosis was 6.0 years (IQR 2.3-10.0) and median treatment duration was 4.0 years (IQR 0.0-8.0), 50% had undetectable viral load. The frequency of anatomical cardiac abnormalities was low and did not differ between people with and without HIV. We observed no relation between HIV or anti-retroviral therapy (ART) and systolic or diastolic heart function. There was an association between ART use and corrected QT interval: +11.8 ms compared to HIV-negative controls (p<0.01) and +18.9 ms compared to ART-naïve participants (p = 0.01). We also observed a higher left ventricular mass index in participants on ART (+7.8 g/m2, p<0.01), but this association disappeared after adjusting for CD4 cell count, viral load and HIV-duration.
CONCLUSION
The low number of major cardiac abnormalities in this relatively young, well managed urban African HIV-positive population is reassuring. The increase in corrected QT interval and left ventricular mass may contribute to higher cardiac mortality and morbidity in people living with HIV in the long term.
Identifiants
pubmed: 33529208
doi: 10.1371/journal.pone.0244742
pii: PONE-D-20-24565
pmc: PMC7853516
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244742Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Cardiol. 1998 Mar 13;64(1):63-73
pubmed: 9579818
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
Cardiovasc Drugs Ther. 2015 Feb;29(1):31-9
pubmed: 25749869
JACC Heart Fail. 2013 Feb;1(1):1-20
pubmed: 24621794
Circulation. 2002 Apr 23;105(16):1928-33
pubmed: 11997279
Eur Heart J. 2014 Jun 1;35(21):1373-81
pubmed: 24408888
J Cardiovasc Med (Hagerstown). 2013 Oct;14(10):733-9
pubmed: 24335884
Circulation. 2005 Dec 6;112(23):3602-7
pubmed: 16330702
HIV Med. 2012 Sep;13(8):453-68
pubmed: 22413967
J Am Coll Cardiol. 2017 Jan 3;69(1):83-91
pubmed: 28057254
Infection. 2017 Oct;45(5):659-667
pubmed: 28776165
Postgrad Med J. 2002 Nov;78(925):678-81
pubmed: 12496326
JACC Heart Fail. 2015 Aug;3(8):579-90
pubmed: 26251085
J Am Coll Cardiol. 1998 Nov;32(5):1454-9
pubmed: 9809962
J Infect Dis. 2010 Feb 1;201(3):318-30
pubmed: 20039804
AIDS Res Hum Retroviruses. 2009 May;25(5):475-81
pubmed: 19397399
Infect Dis Clin North Am. 2014 Sep;28(3):323-37
pubmed: 25151559
Hypertension. 2004 Aug;44(2):175-9
pubmed: 15226274
BMJ Open. 2014 Oct 14;4(10):e005950
pubmed: 25763797
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
J Card Fail. 2018 Aug;24(8):496-503
pubmed: 29964194
Niger J Clin Pract. 2017 Jun;20(6):716-723
pubmed: 28656926
Clin Infect Dis. 2012 Aug;55(4):600-7
pubmed: 22610928
Eur J Prev Cardiol. 2016 Jan;23(2):214-23
pubmed: 25882821
N Engl J Med. 2019 Aug 29;381(9):803-815
pubmed: 31339677
Ann Intern Med. 2015 Mar 3;162(5):335-44
pubmed: 25732274
N Engl J Med. 2003 Nov 20;349(21):1993-2003
pubmed: 14627784
Heart. 2019 Apr;105(7):559-565
pubmed: 30366934
N Engl J Med. 1987 Oct 22;317(17):1098
pubmed: 3657876
Ann Intern Med. 1988 Jan;108(1):7-13
pubmed: 2962527
Circ Heart Fail. 2010 Jan;3(1):132-9
pubmed: 19933410
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Arch Intern Med. 2011 Apr 25;171(8):737-43
pubmed: 21518940
J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):224-233
pubmed: 30640204
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
J Clin Endocrinol Metab. 2007 Jul;92(7):2506-12
pubmed: 17456578
Epidemiology. 2011 Sep;22(5):660-70
pubmed: 21709561
Am J Respir Crit Care Med. 2008 Jan 1;177(1):108-13
pubmed: 17932378
J Infect. 2007 Jun;54(6):597-602
pubmed: 17174400
AIDS Res Hum Retroviruses. 2013 Jan;29(1):20-4
pubmed: 22891715